Vectors based on hybrids consisting of adeno-associated virus types 2 (ITRs and Rep) and 5 (Cap) were evaluated for muscle-directed gene transfer (called AAV2/5). Evaluation in immune-competent mice revealed greater transduction efficacy with AAV2/5 than with AAV2 and no cross-neutralization between AAV2/5 and AAV2. Interestingly, we saw no immunologic evidence of previous exposure to AAV5 capsids in a large population of healthy human subjects.
Vectors based on the human parvovirus adeno-associated virus (AAV) are being evaluated in preclinical and clinical models of gene therapy. The majority of experiments have been performed with vectors based on serotype 2 (14) . A number of principles have emerged from these studies. A wide spectrum of permissivity for AAV2 vector transduction exists, ranging from skeletal muscle, where transduction rates are high, to hematopoietic stem cells, which require large vector doses for detection of transduction. When achieved, transgene expression is remarkably stable and largely void of destructive T-cell responses to nonsecreted transgene products (11, 13) .
Six serotypes of AAV have been isolated and fully characterized with respect to nucleotide sequence (8, 12, 15, 16) . Serotype 5 was isolated from a human condylomatous skin lesion, while the other serotypes were identified as contaminants of human adenovirus preparations (3, 6, 12) . Serotypes 1, 2, 3, and 4 represent distinct molecular isolates with significant homology, particularly in the inverted terminal repeat (ITR) and Rep regions; within this group, Rep proteins can bind to heterologous ITRs and support rescue and replication. Serotype 6 represents a hybrid virus consisting of serotypes 1 and 2. Serotype 5 is quite dissimilar to the others, with a distinct ITR structure and only 67% homology of the rep gene to that of AAV2 (7) .
Other investigators have generated vectors based on AAV5 by using an AAV5 rep-cap genome for production of vector and a vector with AAV5 ITRs. They have shown enhanced performance in terms of transduction efficiency in the murine lung, central nervous system, and most recently, in skeletal muscle (5, 10, 17) .
In this study, an AAV vector based on serotype 5 was generated by transfection of the vector (i.e., ITRs and transgene), a rep-cap-expressing construct, and a plasmid expressing E2a, E4-orf6, and VA from adenovirus (2) . The standard AAV5 vector was produced with an AAV5 rep-cap construct together with a vector containing AAV5 ITRs; the recombinant virions were purified by cesium chloride sedimentation (called AAV5).
A "pseudotyped" version of AAV2 was created by using rep from AAV2 and cap from AAV5 together with a plasmid containing a vector based on AAV2; this was also purified by cesium chloride sedimentation. The resulting vector is referred to as AAV2/5. In comparing the performance of vectors based on AAV2 versus AAV2/5, we utilized common production protocols but different methods of purification. The AAV2 vector was purified by heparin chromatography, which has been shown by several investigators to yield vectors substantially more potent than those purified by cesium chloride sedimentation (2, 18) . This is due, in part, to the inactivation of AAV2 in the presence of cesium chloride during extended centrifugations (2) . Heparin chromatography is not useful for the purification of AAV2/5, since it recognizes a different receptor. Instead, we used cesium chloride sedimentation, which provides a valid comparison to heparin-purified AAV2, since AAV2/5 was not appreciably inactivated by cesium chloride (data not shown). Initial experiments evaluated the expression of CMV lacZ in mouse skeletal muscle injected with equal quantities of the AAV2, AAV5, and AAV2/5 vectors. Histochemical analysis revealed lacZ expression from AAV2/5 ( The yield of the AAV2/5 vector is essentially identical to that of the AAV2 vector when standard transfection approaches are used. Table 1 summarizes the yield, based on the number of genome copies, of seven vectors packaged with either an AAV2 or an AAV2/5 construct. A quantitative analysis of lacZ expression from the AAV2 or AAV2/5 vector following injection into murine skeletal muscle revealed a twofold increase from the AAV2/5 vector. Enzymatic analysis for ␤-galactosidase (␤-gal) from tissue homogenates demonstrated averages of 3.6 Ϯ 0.1 g of ␤-gal/g of tissue for AAV2 and 7.3 Ϯ 1.2 g of ␤-gal/g for AAV2/5 (n ϭ 6; Ϯ 1 standard deviation).
The AAV2/5 lacZ vector was evaluated in a number of other tissues. Subcutaneous injection of the vector led to substantial lacZ expression in smooth muscle cells ( Fig. 1E and F) . The AAV2/5 vector more efficiently infected differentiated airway epithelial cells from the apical surface (Fig. 1G ) than did AAV2 (Fig. 1H) , which is consistent with the results obtained by Zabner et al. with the AAV5 vector (17) .
One advantage of the AAV2/5 vector is that it should be serologically distinct from AAV2 based on antibody neutralization. This may allow in vivo gene transfer in patients with preexisting immunity to AAV2, which represents approximately 25% of healthy subjects (9) and may facilitate readministration with AAV2/5 following infusion with the AAV2 vector.
To test for cross-neutralization in vivo, experiments were conducted with immune-competent mice injected intramuscularly with an AAV2 or AAV2/5 enhanced green fluorescent protein (eGFP) vector, followed 28 days later by an intramuscular injection into the contralateral leg of an AAV2 or AAV2/5 lacZ vector. Expression of ␤-gal was evaluated by enzymatic analysis of tissue homogenates harvested 14 days after the second injection.
Immunization with AAV2 eGFP diminished the effectiveness of a subsequent administration of AAV2 lacZ 20-fold but had no effect on expression from an AAV2/5 vector (i.e., gene expression equivalent to that observed in naive animals; Fig.  2A ). The reverse experiment yielded identical results: immunization with AAV2/5 blocked AAV2/5 readministration but not AAV2 gene transfer and expression (Fig. 2B) .
A cohort of 85 human volunteers previously evaluated for neutralizing antibodies to AAV1 and AAV2 were evaluated for neutralizing antibodies to AAV2/5. We were surprised to see that not a single subject demonstrated neutralizing antibodies to AAV2/5 despite the presence of neutralizing antibodies to AAV1 and AAV2 in 19 and 25% of the subjects, respectively (Fig. 3) . The lack of neutralizing antibodies to AAV5 in our study contrasts with a previous study of AAV5 seroepidemiology performed in 1984 by Geog-Fries et al. (12) with an enzyme-linked immunosorbent assay (ELISA) which detected antibodies to AAV5 capsid proteins in 60% of the individuals tested. Our experience with AAV2 suggests that the ELISA is a more sensitive, and potentially less specific, assay for a specific serologic response; of 74 subjects analyzed, 96% were ELISA positive for AAV2 while only 32% were able to neutralize an infection with AAV2 (9) .
The absence of neutralizing antibodies to AAV2/5 is potentially important for human applications. In contrast to AAV2, where at least a quarter of all patients may have diminished vector engraftment due to preexisting immunity, AAV2/5 uptake should not be affected by immune status in the context of primary vector administration. How can one reconcile the absence of AAV2/5 neutralizing antibodies in humans with the finding that AAV5 was isolated from a human skin lesion?
FIG. 1. AAV5-based cytomegalovirus (CMV) lacZ was derived from plasmid pAAV5 Rn (6), while the AAV5 packaging construct pack 5 was derived from viral AAV5 DNA (3). The hybrid packaging construct pack 2/5 was created by exchanging AAV2 cap from the AAV2 packaging construct p600 trans (2) with AAV5 cap. The AAV2-based AAV CMV lacZ construct has been described previously (2) . a GC, genome copies; CMV, CMV promoter; TBG, thyroxine-binding globulin promoter; rhCG, gene for rhesus chorionic gonadotropin; cFIX, gene for canine factor IX; W, woodchuck hepatitis virus posttranscriptional regulatory element; minsM, gene for furin-modified mouse proinsulin. Average numbers of genome copies were calculated when more than one recombinant AAV preparation was produced.
Several possibilities exist. The initial isolate could have been a contaminant, the incidence of a natural infection may be low, or the systemic serologic response of a natural infection is undetectable.
In summary, vectors based on AAV2/5 may have a number of advantages for muscle gene therapy. Efficacy of transduction in mice is higher than with AAV2 and may be even further improved if a better purification method is developed. Furthermore, preexisting immunity should not be a problem in humans. Testing in other models, such as nonhuman primates, will be important in further evaluating these potential disadvantages.
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